Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phentermine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phentermine SCHEMBL10392295 | 1.00 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL28729624 | 0.97 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL28695767 | 0.97 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL41585 | 0.97 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL3676484 | 0.97 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL25214698 | 0.95 | SLC6A2 (0.91) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL29261099 | 0.95 | SLC6A2 (0.91) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL677133 | 0.95 | SLC6A2 (0.91) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| SCHEMBL11709671 | 0.91 | SLC6A2 (0.83) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A | |
| Phentermine SCHEMBL11072448 | 0.89 | SLC6A2 (0.79) | SLC6A2TAAR1SLC6A4SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28362 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075465-A | Use of propionyl carnitine for improving obesity and insulin resistance | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-121202992-B | Novel long-acting Amylin receptor agonist and application thereof | Hangzhou Nuo Ao Biopharmaceutical Technology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122060114-A | Temporary plugging material for shale gas steering fracturing, preparation method and temporary plugging agent | 中国石油集团渤海钻探工程有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-114008013-B | Treatment of CNS disorders with sleep disorders | 哥本哈根大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122031677-A | Leptin receptor agonist antibodies for the treatment of metabolic dysfunction or hypoleptinemia | 瑞泽恩制药公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260128144-A1 | Systems and Methods for Pharmacotherapeutic Intervention in Obesity Treatment Targeting Multiple Neurophysiological Mechanisms Using Patient Phenotyping Modeling | INTELLIHEALTH INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12611388-B1 | Weight loss formulation and methods | ALLEN GREGORY SETH (US) | 2026-04-28 | — | — | US | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | claimed |
| EP-0142940-A2 | N-acyl glycopeptide derivatives | ELI LILLY AND COMPANY (US) | 1985-05-29 | — | — | EP | claimed |
| US-4479932-A | DIHYDROPYRIDINE PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1984-10-30 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4255439-A | Means and method for aiding individuals to stop smoking | COOPER IRVING | 1981-03-10 | — | — | US | claimed |
| US-4221778-A | ION EXCHANGE RESINS, ANTISWELLING AGENTS | PENNWALT CORPORATION (US) | 1980-09-09 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |